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Abstract
Purpose: Superﬁcial dose is an important parameter in breast cancer radiation therapy. When treated with conventional linacs, bolus is
commonly applied to improve target coverage near the surface while also managing the risk of severe skin reactions and negative
cosmesis. With the introduction of modern linacs with 6X ﬂattening ﬁlter free (FFF) photon beams, the effect on superﬁcial dose and the
need for bolus must be evaluated.
Methods and Materials: In vivo measurements of superﬁcial dose were made with optically stimulated luminescence dosimeters on 11
breast cancer patients treated with the Halcyon 6X FFF linac (Varian Medical Systems, Palo Alto, CA). Additionally, measurements
were made with the Halycon 6X FFF beam and a 6X beam with ﬂattening ﬁlter (FF) delivered to an anthropomorphic phantom. A
planning study was carried out in which 14 patients treated on the Halcyon were replanned with a conventional linac to determine the
difference in superﬁcial dose predicted by the treatment planning system. Measures were taken to increase the accuracy of the treatment
planning system superﬁcial dose.
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Results: The use of the Halcyon 6X FFF beam led to higher superﬁcial dose compared with 6X FF beams. The in vivo measurements
show an average superﬁcial dose of 83.8%  0.6%, which is an increase of approximately 10% compared with published measurements
for a 6X FF linac. Comparison of superﬁcial dose for 6X FF and 6X FFF beams in the phantom measurements show an increase from
70%  1.3% to 84%  1.3%, which is consistent with the in vivo measurements. The planning comparison shows an increase in V70%
Rx from 62%  4.4% to 81%  2.2% for the superﬁcial breast tissue for the Halcyon 6X FFF beam compared with a standard C-arm
linac with FF.
Conclusions: The use of the Halcyon 6X FFF beam was associated with higher superﬁcial dose which may obviate the use of bolus.
 2019 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
A common strategy in treating breast cancer is a com-
bined approach, which involves either mastectomy or
breast-conserving surgery followed by adjuvant radiation
therapy.1 Adjuvant radiation is more common after breast-
conserving surgery; however, post mastectomy radiation
therapy (PMRT) can also be recommended for patients with
advanced stage II or III disease.2 Chest wall recurrences
after mastectomy often involve the scar, subcutaneous tis-
sue, or the dermis itself.1 It is common in post mastectomy
radiation therapy to use a layer of water equivalent bolus
material, typically either 0.5 cm daily or 1 cm every other
day, to increase the dose to superﬁcial tissue while also
managing the risk of excessive skin toxicity.3
The Halcyon (Varian Medical Systems, Palo Alto, CA)
is a novel medical accelerator that features a straight-
through linac with a single 6 MV ﬂattening ﬁlter free
(FFF) beam in an enclosed bore geometry. The removal
of the ﬂattening ﬁlter increases the dose rate and reduces
the scatter and leakage radiation, which in turn reduces
the shielding requirements, lowering cost. The enclosed
bore geometry allows the gantry to rotate 4 times faster
than a C-arm linac without risk of collision with the pa-
tient. This, combined with the higher dose rate of the FFF
beam, reduces treatment time and consequently increases
the patient throughput.4,5
A consequence of the removal of the ﬂattening ﬁlter for
Varian linacs is that the mean energy of the beam is lower
than a ﬂattened beam of the same nominal energy. The
disproportionate attenuation of low energy photons leads to
beam hardening in linacs with ﬂattening ﬁlters. This hard-
ening effect is reduced in FFF beams because there is
signiﬁcantly less material in the beam path, leading to
higher superﬁcial dose.6 Also, Monte Carlo (MC) studies
have shown that the ﬂuence of contamination electrons is
greater in FFF beams, which contributes further to the rise
in superﬁcial dose.7,8 Published studies have demonstrated
an increase in mean energy at the surface and superﬁcial
dose for standard C-arm linacs in FFF mode in both MC
simulations7,8 and commissioning beam data.5,9 Another
important consequence of the Halcyon design that may
affect superﬁcial dose is the presence of the bore cover in
the beampath, whichmay act like a beam spoiler increasing
the superﬁcial dose to the patient.
Given these factors, the superﬁcial dose must be
assessed in breast cancer patients treated with Halcyon to
determine the appropriate treatment techniques for the
management of skin coverage and toxicity, in particular
the need for bolus.
Methods and Materials
In vivo measurements
Superﬁcial dose measurements were carried out on 11
breast cancer patients treated on Halcyon at the University
of Pennsylvania Perelman Center for Advanced Medicine
between March and November 2018. The prescription
doses ranged from 4005 to 5040 cGy to the whole breast
with a local boost of 1000 cGy to the surgical bed in some
cases. Measurements were made at 9 locations across the
surface of the breast for each patient using Landauer
Nanodot optically stimulated luminescence detectors
(OSLDs). Figure 1a shows an example of the OSLD
placement for a patient in the study. Two OSLDs were
placed at each location, each OSLD was read 5 times, and
the average of all 10 readings was used to estimate the
superﬁcial dose in that region. Table 1 shows a summary
of the characteristics of the patients included in the in vivo
measurement study.
Landauer nanodots are composed of carbon doped
aluminum oxide (Al2O3:C) disks, 7 mm in diameter and
0.2 mm thick enclosed in a 1 cm  1 cm  2 mm light
tight plastic casing of 0.04 g/cm2 intrinsic buildup.10 The
OSLD batch was calibrated following the vendor rec-
ommended procedure.11 The calibration was then vali-
dated to an accuracy of  1.5%, which is within the
accuracy of 5% claimed by the vendor.
The treatment plans for all patients were generated
using the Eclipse treatment planning system version 15.5-
6 with the AAA dose calculation algorithm and Halcyon
version 1.0 and version 2.0. Part way through the study
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the Halcyon was upgraded from version 1.0 to version 2.0
to include kV cone beam CT (CBCT) imaging capability.
To support this upgrade, Eclipse was also upgraded from
version 15.1 to version 15.6. The ﬁrst 5 patients were
treated on Halcyon version 1 with MV CBCT. The
remaining 6 patients were treated on version 2 with kV
CBCT. A CBCT was taken for all patients at every
fraction to ensure proper alignment. This is necessary
because the Halcyon has no light ﬁeld or optical distance
indicator. The OSLDs were placed before the CBCT so
the raw measurements include the combined dose from
the imaging and treatment ﬁelds. However, phantom and
in vivo measurements of the CBCT dose on Halcyon
indicate that it is a negligible contribution to the total dose
for both kV and MV CBCT. Nevertheless, the CBCT
dose was subtracted from the raw measurements to
consider the dose from the treatment ﬁelds only because
imaging practice may vary between institutions.
The treatment plans for all but one of the patients for
which measurements were taken were generated using the
electronic tissue compensation12 technique in which
MLCs are swept across the ﬁeld to produce a
homogeneous dose in the target. The remaining patient
was treated with the standard ﬁeld-in-ﬁeld technique.
Phantom measurements
To study the difference in superﬁcial dose in a
controlled setting, phantom measurements were made
with OSLDs in the same conﬁguration as described for
the patient measurements. 6X FF and FFF tangential
ﬁelds were delivered, with TrueBeam (Varian Medical
Systems, Palo Alto, CA) and Halcyon linacs, respectively,
to an anthropomorphic Rando phantom (Imaging Solu-
tions, Brisbane, Australia) with a 2-cm layer of bolus used
to simulate breast tissue attached to the right anterior chest
of the phantom. The superﬁcial dose for the FF ﬁelds on
TrueBeam was measured with and without a 1-cm bolus
placed on top of the OSLDs. The measurements were
used to estimate the superﬁcial dose for Halcyon and a C-
arm FF linac with and without bolus and with bolus
applied on alternate days which is a common clinical
practice. The phantom setup with the bolus and OSLDs
placed is shown in Fig 1b. These measurements allow for
a direct comparison between 6X FF and FFF ﬁelds
measured with the same detector system and setup.
For each set of phantom measurements, a CBCT was
done before delivering the treatment ﬁelds to ensure that
all OSLDs were well within the treatment ﬁelds. An extra
OSLD pair was placed in the center of the breast for the
CBCT only to estimate its contribution to the total dose.
Treatment plans were generated on the phantom with
the Eclipse TPS version 15.5-6 for Halcyon and True-
Beam with opposed tangent ﬁelds and a prescription of
4256 cGy in 266 cGy fractions. An additional plan was
optimized for TrueBeam with a 1-cm bolus added in
planning. A volume was drawn to simulate a typical
Table 1 Patient characteristics: summary of the patient
characteristics for the in vivo and planning studies





Right 8 (72.7%) 8 (57.1%)
Left 3 (27.3%) 6 (42.8%)
Position
Supine 9 (81.8%) 12 (85.7%)
Prone 2 (18.2%) 2 (14.3%)
Target
Whole breast 6 (54.6%) 12 (85.7%)
Whole breast þ LNs 5 (45.4%) 2 (14.3%)
Surgery
Intact breast 7 (63.6%) 12 (85.7%)
Mastectomy without
reconstruction
3 (27.3%) 2 (14.3%)
Mastectomy without
reconstruction
1 (9.1%) 0 (0.0%)
Figure 1 (a) In vivo setup: image of patient taken before
treatment showing array of optically stimulated luminescence
detectors. (b) Phantom setup: Rando phantom setup showing the
optically stimulated luminescence detector placement for the
phantom measurements.
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breast target and the plans were optimized to achieve
approximately the same target coverage.
Treatment planning system calculated dose
comparison
To complement the patient and phantom measure-
ments, a planning study was carried out to make a direct
comparison of the superﬁcial dose calculated in the
treatment planning system (TPS). This comparison
removes complicating factors that may inﬂuence the su-
perﬁcial dose such as variations in patient anatomy and
OSLD placement. However, it is subject to other limita-
tions, namely the accuracy of the TPS dose calculation
algorithm near the patient surface. Measures were taken to
reduce this uncertainty to allow for a meaningful com-
parison of superﬁcial dose.13
Fourteen breast patients planned and treated on the
Halcyon were retrospectively replanned with either a
Clinac (Varian Medical Systems, Palo Alto, CA) or
TrueBeam 6 MV FF beam model. These are collectively
referred to in the following as C-arm FF linac. The plans
were renormalized to achieve approximately the same
target coverage and were required to meet all clinical
constraints. The study includes a wide range of clinical
and treatment characteristics, such as laterality, treatment
position, and planning techniques, which are summarized
in Table 1. Of the 14 patients in the study, 11 were
planned on Halycon with Varian’s implementation of the
electronic tissue compensation technique known as the
irregular surface compensator, 2 were planned using the
ﬁeld-in-ﬁeld (FiF) technique with dynamic beam ﬂat-
tening and one with the FiF technique with the native FFF
beam. All the comparative C-arm FF linac plans were
planned with the FiF technique and reviewed by a
physician and deemed clinically acceptable.14
For all patients treated in the supine position, 2
treatment plans were generated with and without a 1 cm
bolus and an equally weighted plan sum of the 2 was
generated to represent the common clinical practice of
applying bolus on alternate days throughout the course
of treatment. The superﬁcial dose was then compared
between the Halcyon plans and the standard C-arm FF
linac plans.
A well-known limitation of TPS dose calculation al-
gorithms, including the Eclipse AAA algorithm imple-
mented in this study, is the underestimation of dose in the
superﬁcial region. A study comparing AAA to MC sim-
ulations and phantom measurements shows that this un-
derestimation can be reduced from 14% to 4% without
affecting the dose to underlying structures by extending
the body contour by 2 cm into the air surrounding the
patient.13 This recommendation was implemented in the
present study to improve the accuracy of the superﬁcial
dose comparison.
A superﬁcial tissue structure was deﬁned as a 2-mm
inner margin on the patient contour deﬁned with a
threshold CT number of e800 HU. This is the smallest
thickness at which the TPS can generate a continuous
structure owing to the limited segmentation resolution. A
superﬁcial breast tissue structure was then taken as the
overlap of the superﬁcial tissue structure and a 2-cm
expansion on the breast target structure. Each structure
was deﬁned as a high-resolution contour in the planning
system to capture the superﬁcial tissue as accurately as
possible.
All data were analyzed using MatLab R2017a Statistics
toolbox (The MathWorks Inc, Natick, MA). Statistical
signiﬁcancewas assessed at the 95% conﬁdence level using
a 2-sided Student t test comparing 2 unpaired distributions
with unequal variance, also known as a Welch t test.
Results
Figure 2 shows a histogram of all Halcyon in vivo and
phantom surface dose measurements. There are a total of
228 measurements with a mean value of 83.8%  0.6% of
the prescription dose. The error is calculated as the stan-
dard error of the mean Z s/On. The histogram is ﬁt to a
Gaussian, yielding a ﬁt mean and standard deviation of
83.9% and 8.3%, respectively with a c2d value of 2.2.
The mean of the Halcyon in vivo and phantom mea-
surements considered separately are 83.8  0.6% and
84  1.3%, respectively.
The distribution of measurements for each individual
patient, including the mean and the spread of the data are
shown in Figure 3. The plot also shows the distribution of
phantom measurements treated with breast tangents on
the Halcyon, the TrueBeam with and without bolus and
with bolus applied on alternate days. The average super-
ﬁcial dose measured on the Rando phantom irradiated
Figure 2 Superﬁcial dose histogram: histogram of all super-
ﬁcial dose measurements for the 11 breast cancer patients and
the Rando phantom treated on Halcyon.
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with the TrueBeam breast plan is 70%  1.3% without
bolus, 104%  2% with bolus, and 87%  1.3% with
bolus applied on alternate days. The superﬁcial dose for
the Halcyon phantom measurement is 84%  1.3% which
demonstrates an increase of approximately 14% with
respect to TrueBeam. This is consistent within measure-
ment error with the difference seen in the in vivo study.
The OSLDs were placed before imaging and therefore
included the dose from the CBCT. This represents a very
small contribution to the overall dose. The dose from
CBCT alone was estimated with an OSLD measurement
of the CBCT ﬁeld and found to be 0.8  0.1 cGy for the
MV CBCT and 0.27  0.01 cGy for the kV CBCT, which
is <0.5% of the prescription for all patients. For the kV
CBCT dose the OSLD response was scaled down by a
factor of 3.5 to account for the known over response of
Al2O3:C OSLDs to kilovoltage x-rays.
10,15 The CBCT
dose was then subtracted from all measurements to
consider the dose from the treatment ﬁelds only.
Figure 4 show the results of the TPS superﬁcial dose
comparison. Figure 4a shows a comparison of the average
dose volume histogram (DVH) for the superﬁcial breast
tissue for the 4 scenarios considered: C-arm FF linac,
Halcyon and C-arm FF linac with and without bolus and
with bolus applied on alternate days. Figure 4b shows
the distributions of 3 dose volume parameters (Dmax,
Dmean
, and V70%Rx) for the superﬁcial breast tissue in
these 4 scenarios.
The results of the TPS dosimetry study indicate that
the AAA dose calculation algorithm also shows an in-
crease in superﬁcial dose for Halcyon compared with a
standard C-arm FF linac. However, the superﬁcial dose
is still less than that for a C-arm FF linac with bolus
applied every other day. This is consistent with the
in vivo and phantom measurements. The mean dose to
the superﬁcial breast tissue for Halcyon and C-arm FF
linac is 76.7%  0.8% and 73%  1.6% respectively
(P Z .017). The average value of V70%Rx is
81%  2.2% for Halcyon and 62%  4.4% for the C-
arm FF linac (P < .01). This increase is clearly visual-
ized in the average DVH comparison plot in Figure 4b.
No signiﬁcant dosimetric differences were observed for
other organs at risk other than a moderate increase in
mean heart dose for Halcyon due to the daily CBCT.
Published studies have demonstrated that treatment plans
generated for breast cancer with ﬂattened and FFF beams
are dosimetrically comparable for structures other than
superﬁcial tissue.16
Figure 3 Superﬁcial dose versus patient: in vivo superﬁcial
dose measurements made with optically stimulated lumines-
cence detectors for the 11 patients in the study and on the Rando
phantom treated with tangential ﬁelds on the Halcyon, True-
Beam with and without bolus and with bolus applied on alter-
nate days. The boxes represent the range of data from the 25% to
the 75% percentile and whiskers are drawn to the furthest ob-
servations not considered outliers (outliers deﬁned as
>1.5  range).
Figure 4 (a) Breast skin DVH comparison: comparison of the
breast skin DVH for the C-arm linac (yellow), Halcyon (dark
yellow), C-arm linac with bolus applied every other day (or-
ange), and C-arm linac with bolus (red). The dashed curve and
bands represent the average and 1 sigma variation of the DVHs
across all 14 patients in the planning study. (b) Breast skin
dosimetry: comparison of Dmax, Dmean, and V70%Rx of the
breast skin structure calculated in eclipse for the same 4 sce-
narios. DVH Z dose volume histogram.
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Discussion
The in vivo and phantom measurements demonstrate
that the average surface dose in breast cancer treatment
with tangential ﬁelds is signiﬁcantly higher on the
Halcyon than on a conventional C-arm 6 MV linac with
ﬂattening ﬁlter. Similar in vivo measurements made by
Soleymanifard et al, with thermo-luminescent dosimeters
on a C-arm linac with 6 MV beams and ﬂattening ﬁlter
yield an average value of 74.4%  4.5%.17 The surface
dose measured on Halcyon in our study is approximately
10% higher (P Z .046).
To rule out the possibility that the observed difference
in superﬁcial dose is caused by the difference in effective
buildup of the dosimeters, additional phantom measure-
ments were carried out on a TrueBeam with 6X FF
tangential beams. As shown in Fig 4, these measurements
are consistent with those presented by Soleymanifard
demonstrating that the difference is in fact due to the linac
rather than the dosimeters. Also of note, the Halcyon
phantom measurement is comparable to that on the
TrueBeam with bolus applied alternately with a difference
of only 2.6% (P Z .028).
Given the geometry of tangential ﬁelds and the irregular
shape of the breast contour the superﬁcial doses presented
here represent an average over a range of angles of inci-
dence. To provide a reference to zero angle of incidence
measurements were carried out on the Halcyon and True-
Beam of an en face 10 10 cm2 beam at 100 SSD in solid
water with a PTW TN34045 Markus plan parallel chamber
(PTW-Freiburg, Freiburg, Germany). The measurements
yield superﬁcial doses of 26.8% at the surface and 57.9% at
1-mm depth for Halcyon and 19.7% at the surface and
47.4% at 1-mm depth for TrueBeam. Thus, for an en face
ﬁeld the superﬁcial dose for Halcyon is approximately 8%
to 11% higher than TrueBeam, which is consistent with the
increase seen for the breast ﬁelds.
It was observed that the relative increase in superﬁcial
dose predicted by AAA for Halcyon versus C-arm FF
linac was smaller compared with that observed in the
in vivo and phantom measurements. This is most likely a
reﬂection of the limited accuracy of the surface dose
modeling in the current AAA algorithm (version 15.6.03).
Caution should be taken when evaluating superﬁcial dose
for Halcyon plans as it might underestimate the actual
dose received by superﬁcial structures.
The extent to which the observed increase in superﬁ-
cial dose was inﬂuenced by the spoiler effect of the bore
cover was tested by making a series of measurements with
and without the bore cover. Percent depth dose curves
were measured with a parallel plate chamber in water for a
10  10 ﬁeld at 80 cm and 100 cm SSD. Figure 5 shows
the difference in these measurements in the superﬁcial
region. It can be observed that the difference with and
without the bore cover is minimal (<1%), suggesting that
it is not the main contributor to the higher superﬁcial dose
observed for Halcyon 6 FFF beams. This implies that the
increase is caused primarily by the lower average energy
of the beam and the higher ﬂuence of contamination
electrons in the absence of the ﬂattening ﬁlter.
Conclusions
The combination of in vivo and phantommeasurements
establishes that there is a signiﬁcant increase (10%-15%) in
superﬁcial dose for whole breast irradiation with Halcyon
compared with a standard 6X linac with ﬂattening ﬁlter.
The superﬁcial dose with Halcyon is approximately equal
to that achievedwith a standard 6X linac by applying a 1-cm
bolus for half of the treatment fractions. Comparison of the
dose calculated with the Eclipse TPS also shows an in-
crease; however, it does not reﬂect the full magnitude of the
increase observed in the in vivo measurements. The results
of the study suggest that it may be possible to cover the full
breast or chest wall after mastectomywith sufﬁcient dose to
superﬁcial and subcutaneous tissues without applying
bolus. The traditional strategy of applying bolus every other
day should be carefully re-evaluated to reduce the chance of
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